Treatment of adult rhabdoid renal cell carcinoma with sorafenib

  • Anil Kapoor Division of Urology, Department of Surgery; and Section of Genito-Urinary Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ont.
  • Robert Tutino Division of Urology, Department of Surgery, McMaster University, Hamilton, Ont.
  • Androniki Kanaroglou Division of Urology, Department of Surgery, McMaster University, Hamilton, Ont.
  • Sebastien J. Hotte Section of Genito-Urinary Oncology, Juravinski Cancer Centre, Hamilton, Ont.

Abstract

Renal cell carcinoma (RCC) with rhabdoid features is an uncommon and highly aggressive malignancy. We report a case of adult clear-cell RCC with extensive rhabdoid features treated with the tyrosine kinase inhibitor sorafenib. A review of the literature summarizes important aspects of this malignancy. We discuss clinical and histological findings as well as the patient’s response to sorafenib therapy.
Published
2008-12-01
How to Cite
Kapoor, A., Tutino, R., Kanaroglou, A., & Hotte, S. J. (2008). Treatment of adult rhabdoid renal cell carcinoma with sorafenib. Canadian Urological Association Journal, 2(6), 631. https://doi.org/10.5489/cuaj.983
Section
Case Report